(The TQCC of Pharmacoeconomics is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)271
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)183
Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018102
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment80
International Valuation Protocol for the EQ-5D-Y-3L78
A Comparison of the EQ-5D-3L and EQ-5D-5L64
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis58
Calculating and Interpreting ICERs and Net Benefit56
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study48
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach45
Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States45
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers43
EQ-5D-Y Value Set for Slovenia42
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations37
Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment37
Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates31
Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines31
Why it’s Time to Abandon the ICER30
Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers28
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review26
Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice25
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness25
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review24
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension24
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies23
Integrative Review of Managed Entry Agreements: Chances and Limitations23
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures22
Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden21
Economic Costs of Myasthenia Gravis: A Systematic Review21
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study21
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine21
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel21
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China20
The Application and Implications of Novel Deterministic Sensitivity Analysis Methods20
Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP Disparity20
Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures19
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States19
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective19
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis19
Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering18
Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model17
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria16
Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Out16
EQ-5D-Y Value Set for Germany16
Modeling Heterogeneity in Patients’ Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches15
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review15
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US15
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review15
Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden15
Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review14
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer14
‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases14
Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic13
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates13
Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis13
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma13
Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer13
Modifying NICE’s Approach to Equity Weighting13
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review13
Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff13
Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies13
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups13
Value Set for the EQ-5D-Y-3L in Hungary13
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia12
Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US12
A Comparison of PROPr and EQ-5D-5L Value Sets12
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review12
Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumati12
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions11
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework11
Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study11
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China11
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision11
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine11
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States11
Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol11
Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest10
Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness10
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve10
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)10
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations10
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe10
Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review10
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US10
Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector10
Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment10
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA10
A Value Set for the EQ-5D-Y-3L in the Netherlands10
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis10
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder10
Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening9
The Costs of Dementia in Europe: An Updated Review and Meta-analysis9
Estimating an EQ-5D-Y-3L Value Set for China9
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management9
The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS)9
Economic Implications of Endometriosis: A Review9
Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal8
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia8
Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis8
The Challenges of Measuring Informal Care Time: A Review of the Literature8
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents8
The EQ-5D-5L Valuation Study in Egypt8
A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom8
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal8
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer8
Postnatal Major Depressive Disorder in Australia: Inequalities and Costs of Healthcare to Individuals, Governments and Insurers8
Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations7
RETRACTED ARTICLE: The EQ-5D-5L Valuation Study in Egypt7
A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population7
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review7
Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden7
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers7
Future of Data Analytics in the Era of the General Data Protection Regulation in Europe7
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden7
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups7
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland7
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)7
Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations7
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic7
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA7
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review7
A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets7
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review7